background
goal
studi
evalu
whether
live
attenu
polioviru
vaccin
opv
clinic
relev
interf
effect
nonpolio
infect
caus
otiti
media
young
children
method
open
trial
intervent
group
children
receiv
opv
age
month
control
group
children
receiv
ipv
inactiv
polio
vaccin
age
month
clinic
symptom
record
questionnair
age
month
result
otiti
media
episod
less
frequent
opv
control
group
signific
differ
seen
age
month
irr
ci
p
particularli
clear
among
children
attend
daycar
irr
ci
p
conclus
opv
provid
protect
otiti
media
effect
may
mediat
viral
interfer
nonpolio
virus
acut
upper
respiratori
infect
uri
like
common
cold
promin
acut
diseas
children
picornavirus
causal
agent
major
case
uri
acut
otiti
media
aom
close
link
case
uri
complic
aom
otiti
media
caus
virus
bacteria
mix
infect
common
common
virus
found
aom
rhinoand
enterovirus
belong
enteroviru
genu
vaccin
wellknown
enterovirus
poliovirus
routin
use
almost
countri
vaccin
avail
enterovirus
finland
well
increas
number
countri
children
routin
vaccin
poliomyel
inactiv
polioviru
vaccin
ipv
salk
vaccin
type
polio
vaccin
oral
live
vaccin
opv
sabin
vaccin
also
use
wide
contrast
ipv
opv
induc
strong
local
immun
respons
gastrointestin
tract
strong
system
cellmedi
immun
respons
previou
studi
shown
cellmedi
immun
respons
poliovirus
crossreact
nonpolio
enterovirus
due
structur
similar
howev
clear
crossreact
provid
crossprotect
nonpolio
enterovirus
addit
replic
opv
strain
prolong
period
lead
longlast
type
interferon
respons
antivir
state
improv
resist
virus
contrast
opv
ipv
lack
properti
ipv
induc
mainli
antibodi
antibodymedi
protect
polioviru
specif
addit
ipv
consid
induc
much
weaker
shorter
type
interferon
secret
viral
interfer
report
number
studi
recent
wang
et
al
notic
neg
associ
presenc
rhinoviru
hrv
adenoviru
hadv
militari
recruit
suggest
viral
interfer
hrv
hadv
addit
start
influenza
pandem
delay
begin
autumn
franc
possibl
due
viral
interfer
rhinovirus
influenza
virus
interfer
may
result
nonspecif
innat
immun
respons
interferon
respons
caus
hrv
induc
refractori
state
respiratori
tract
prevent
infect
respiratori
virus
studi
assess
factor
affect
immunogen
first
two
dose
opv
among
unimmun
mayan
infant
reveal
viral
interfer
also
sabin
type
sabin
type
poliovirus
addit
concurr
enter
nonpolio
enteroviru
infect
seem
lead
reduc
antibodi
respons
sabin
type
object
studi
assess
whether
abovement
properti
live
attenu
polioviru
vaccin
opv
lead
clinic
relev
interfer
nonpolio
virus
therefor
carri
vaccin
trial
studi
effect
opv
occurr
otiti
media
children
younger
year
age
enterovirus
includ
also
rhinovirus
common
caus
otiti
media
hypothes
opv
would
reduc
incid
otiti
media
open
trial
intervent
group
children
boy
girl
vaccin
oral
polio
vaccin
opv
age
month
year
fig
control
group
compris
children
boy
girl
receiv
inactiv
polioviru
vaccin
ipv
age
month
accord
standard
immun
protocol
finland
time
intervent
control
group
match
gender
date
birth
month
hla
type
thu
control
possibl
confound
effect
season
number
infect
hla
infect
immun
children
healthi
newborn
recruit
prospect
type
diabet
predict
prevent
studi
dipp
tamper
univers
hospit
finland
dipp
studi
newborn
infant
whose
famili
gave
inform
consent
studi
first
screen
use
cord
blood
hla
class
ii
allel
confer
suscept
type
diabet
increas
risk
recruit
prospect
followup
setup
made
possibl
match
intervent
control
group
hla
allel
carri
genotyp
x
refer
allel
opv
given
dipp
children
whose
parent
consent
opv
vaccin
recruit
period
immunodefici
malign
diseas
immunosuppress
treatment
maxim
five
control
children
select
opvvaccin
child
larg
cohort
dipp
children
randomli
children
fulfil
match
criteria
describ
alloc
ratio
chosen
maxim
number
particip
ipv
group
follow
normal
finnish
vaccin
schedul
made
possibl
ipv
vaccin
children
tabl
compar
demograph
featur
group
signific
differ
proport
children
breastf
age
month
higher
opv
group
local
ethic
committe
nation
agenc
medicin
finland
approv
studi
written
inform
consent
obtain
parent
studi
children
subject
visit
studi
center
age
month
parent
interview
studi
nurs
use
standard
questionnair
visit
number
aom
episod
child
encount
sinc
last
visit
clinic
record
store
studi
databas
aom
episod
report
parent
diagnos
physician
count
thu
episod
diagnos
doctor
prolong
otiti
media
secretori
otiti
media
count
first
diagnos
acut
phase
inform
diet
type
daycar
care
home
famili
care
daycar
center
also
document
context
visit
number
sibl
pet
record
well
poisson
regress
model
use
multivari
analysi
compar
effect
vaccin
type
gender
start
age
daycar
durat
breastfeed
number
sibl
pet
number
infect
record
match
casecontrol
group
cohort
studi
result
present
incid
rate
ratio
irr
test
use
analyz
statist
signific
differ
observ
smoke
habit
pregnanc
mother
opv
ipv
vaccin
children
softwar
packag
use
spss
version
spss
chicago
il
usa
stata
version
statacorp
colleg
station
tx
usa
differ
consid
signific
p
particip
receiv
polio
vaccin
plan
total
durat
followup
personyear
median
durat
month
altogeth
children
opv
vaccin
ipv
vaccin
complet
entir
followup
opv
group
subject
drop
age
month
ipv
group
drop
age
month
respect
total
number
om
episod
record
averag
per
child
followup
opv
vaccin
children
slightli
less
om
episod
first
year
life
ipv
vaccin
control
averag
number
vs
per
child
irr
ci
differ
statist
signific
p
sinc
protect
effect
opv
probabl
occur
age
vaccin
virus
activ
replic
gut
mucosa
age
month
incid
om
peak
age
month
number
om
episod
analyz
age
month
signific
differ
seen
opv
ipv
group
number
om
episod
age
period
vs
episod
per
child
irr
ci
p
protect
effect
opv
even
stronger
among
subject
start
daycar
alreadi
age
month
earlier
p
fig
analys
adjust
effect
possibl
confound
factor
ie
daycar
pet
breastfeed
number
sibl
acut
om
episod
one
common
reason
child
visit
doctor
age
year
frequent
indic
prescript
antibiot
furthermor
om
caus
signific
econom
loss
famili
societi
virus
play
import
role
etiolog
om
predispos
bacteri
invas
middl
ear
lead
purul
infect
also
estim
acut
om
case
due
viru
infect
without
bacteri
coinfect
picornavirus
includ
rhinoand
enterovirus
common
virus
acut
om
children
follow
close
virus
influenza
viru
parainfluenza
viru
rsv
adenoviru
human
bocaviru
human
metapneumoviru
coronaviru
moreov
rhinovirus
shown
preval
pathogen
lower
respiratori
infect
infant
recent
studi
shown
particularli
ctype
rhinovirus
abl
caus
sever
infect
young
children
viru
infect
often
initi
bacteri
om
would
highli
benefici
prevent
initi
viral
infect
fact
influenza
vaccin
observ
decreas
om
episod
influenza
season
efficaci
better
pneumococc
conjug
vaccin
type
vaccin
may
also
import
protect
conjug
polysaccharid
vaccin
like
heptaval
pneumococc
conjug
vaccin
serotypespecif
protect
infect
caus
serotyp
includ
vaccin
contrast
live
attenu
viru
vaccin
often
induc
viralinterfer
immunolog
crossreact
genet
relat
agent
first
studi
assess
effect
live
attenu
enteroviru
vaccin
opv
nonpolio
infect
childhood
picornavirus
compris
approxim
differ
serotyp
capabl
infect
human
caus
symptom
poliovirus
belong
picornavirus
main
caus
group
virus
caus
acut
om
find
opv
inde
reduc
acut
om
episod
suggest
opv
may
interfer
picornavirus
caus
om
find
also
indirectli
support
earlier
studi
accord
report
concurr
infect
enterovirus
demonstr
interfer
opv
vaccin
infavour
vaccin
epidemiolog
observ
south
america
suggest
nonspecif
intestin
interfer
gener
opv
strain
reduc
mortal
infantil
diarrhea
knowledg
util
bulgaria
univers
administr
opv
appli
help
termin
nonpolioviru
epidem
thu
kind
viral
interfer
seem
clear
biolog
effect
interfer
caus
least
two
differ
mechan
crossprotect
genet
relat
nonpolio
enterovirus
mediat
crossreact
cellular
immun
respons
induct
type
interferon
antivir
innat
immun
system
respons
protect
mani
differ
virus
compar
mani
virus
interf
effect
opv
may
particularli
strong
sinc
replic
vaccin
viru
strain
last
longer
period
mani
virus
replic
week
sometim
even
month
vaccin
individu
lead
longlast
strong
activ
innat
adapt
immun
system
enterovirus
includ
also
rhinovirus
constitut
import
viru
group
caus
om
even
modest
protect
effect
may
import
clinic
impact
known
approxim
children
experienc
least
one
episod
om
age
month
peak
incid
month
sever
risk
factor
om
identifi
find
daycar
number
sibl
male
gender
increas
incid
om
line
previou
observ
fact
protect
effect
opv
seen
particularli
among
children
start
daycar
young
age
probabl
due
strong
exposur
virus
caus
om
addit
protect
effect
strongest
age
month
acut
om
peak
fit
also
time
period
interf
effect
opv
expect
occur
vaccin
given
four
time
age
month
howev
result
interpret
caution
sinc
number
studi
subject
rel
small
certain
possibl
confound
factor
eg
antibiot
treatment
followup
could
taken
account
possibl
confound
effect
vaccin
unlik
sinc
coverag
nation
vaccin
program
high
addit
vaccin
rare
given
data
shown
interestingli
pet
home
independ
protect
effect
om
phenomenon
also
report
previous
reason
known
may
relat
avoid
pet
atop
famili
atopi
risk
factor
om
possibl
booster
effect
pet
immun
protect
infect
recent
studi
suggest
furri
pet
also
reduc
risk
recurr
acut
respiratori
ill
identif
om
episod
base
inform
given
parent
interview
intervent
control
group
interview
prospect
structur
manner
use
standard
questionnair
minim
possibl
bia
record
group
addit
acut
om
lead
usual
quit
clear
episod
diagnosi
alway
made
doctor
studi
also
import
advantag
symptom
record
consecut
visit
studi
clinic
prospect
followup
maximum
time
period
previou
visit
month
thu
like
parent
abl
recal
om
episod
reliabl
short
period
fact
mean
number
acut
om
episod
parent
report
per
childyear
similar
found
previou
studi
suggest
report
episod
quit
reliabl
studi
suggest
live
attenu
enteroviru
vaccin
may
play
role
modul
immun
microbi
infect
protect
effect
opv
om
suggest
interfer
may
provid
import
clinic
benefit
even
though
safeti
profil
opv
may
optim
prevent
om
gener
studi
suggest
live
viru
vaccin
may
benefici
effect
much
wider
origin
indic
therefor
mechan
viral
interfer
induc
live
viru
vaccin
studi
possibl
interf
effect
could
appli
develop
new
vaccin
picornavirusrel
diseas
om
mening
myocard
type
diabet
